kevin outterson mko@bu
DESCRIPTION
New Business Models for Preventing and Treating Bacterial Diseases House Energy & Commerce Committee September 19, 2014. Kevin Outterson [email protected]. A Serious Problem. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/1.jpg)
New Business Models for Preventing and Treating
Bacterial Diseases
House Energy & Commerce Committee
September 19, 2014
Kevin [email protected]
![Page 2: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/2.jpg)
A Serious Problem
HIV Homicide Motor vehicle accidents ABR + c. diff Breast cancer0
5000
10000
15000
20000
25000
30000
35000
40000
45000
US Deaths from various causes, 2011
Source: National Vital Statistics Report (NVSR) “Deaths: Final Data for 2011.” Data for ABR + c. diff. is from CDC, Antibiotic Resistance Threats in the US, 2013
![Page 3: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/3.jpg)
Private Net Present Value (NPV) Model
![Page 4: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/4.jpg)
![Page 5: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/5.jpg)
Broken Business Model
Source: Eastern Research Group. Analytical Framework for Examining the Value of Antibacterial Products (April 2014). Available at: http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm.
![Page 6: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/6.jpg)
Social Net Present Value (NPV) Model
![Page 7: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/7.jpg)
Social NPVs
Source: Eastern Research Group. Analytical Framework for Examining the Value of Antibacterial Products (April 2014). Available at: http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm.
![Page 8: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/8.jpg)
Comparison
ABOM ABSSI CABP CIAI CUTI HABP/VABP
-$2,000
$0
$2,000
$4,000
$6,000
$8,000
$10,000
$12,000
$14,000
Private Social
Source: Author’s analysis of ERG 2014.
![Page 9: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/9.jpg)
HABP/VABP
-$1,500 $500 $2,500 $4,500 $6,500 $8,500 $10,500 $12,500
Social Private
Source: Author’s analysis of ERG 2014. Annual US private and social ENPV by indication, in millions of US$
![Page 10: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/10.jpg)
Source: Author’s analysis of ERG 2014. Annual US private and social ENPV by indication, in millions of US$; social values truncated at $100 million to show private detail
ABOM ABSSI CABP CIAI CUTI HABP/VABP-$20
$0
$20
$40
$60
$80
$100
PrivateSocial
![Page 11: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/11.jpg)
Evaluating Incentives for
Antibacterial Drug Development
![Page 12: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/12.jpg)
Incentive CategoriesTYPE CONSERVATION PRODUCTIONProperty Intellectual property (IP) used as
conservation tools to privately constrain demand
Intellectual property (IP) used as incentives to bring new antibiotics to market
Regulation Public health infection control and antibiotic stewardship programs regulate demand for antibiotics
FDA regulations relaxed to speed approval of new antibiotics. Tax subsidies support R&D
Contract Prizes, grants, and value-based reimbursement support antibiotic conservation.
Prizes, grants, and value-based reimbursement support new antibiotic production.
Tort Patients sue for hospital-associated infections, increasing institutional incentives to promote safety through antibiotic conservation
Federal law designed to preempt state tort law, waiving drug company tort liability for antibiotics
Source: Kesselheim and Outterson, 2010Note: IP collectively refers to Patents, Data Exclusivity (DE), Marketing Exclusivity (ME), Patent Term Adjustments (PTAs), Patent Term Extensions (PTEs), and Supplementary Protection Certificates (SPCs). Even though these are treated in a similar fashion in the model, they vary in terms of purview, structure, and expected impacts.
![Page 13: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/13.jpg)
13
Incentives in Detail
CONSERVATIONREGULATION Public health
infection control and antibiotic stewardship programs regulate demand for antibiotics
1. Education campaigns to encourage appropriate use of antibiotics
2. Regulate the procurement and marketing chain through an ISO standard for public procurement and accreditation of informal drug dispensers in the developing world
3. Expand promotion of vaccination4. Encourage antibiotic substitutes, such as free or
heavily discounted “cold kits” to physicians 5. Coordinate infection control regionally and facilitate
cooperation among hospitals6. Expand surveillance of resistance
…
18. Provide transparency on institutional infection rates and resistance levels
![Page 14: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/14.jpg)
Production Incentives
![Page 15: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/15.jpg)
ERG Report, 3-16 to -18
Incentive Results
![Page 16: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/16.jpg)
• Cost of capital reductions through fully refundable tax credits and/or grants should be in the range of 50%
• Milestone payments, approval prizes and enhanced rbx can significantly improve NPV if large enough (~$1 billion/approval)
What Works
![Page 17: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/17.jpg)
Less Likely• IP (patents, market exclusivity, data
exclusivity) will not significantly impact NPV
• Further (feasible) reductions in clinical trial size and time will not significantly impact NPV
![Page 18: Kevin Outterson mko@bu](https://reader035.vdocument.in/reader035/viewer/2022081418/5681339f550346895d9ab48f/html5/thumbnails/18.jpg)
New Business Models for Preventing and Treating
Bacterial Diseases
House Energy & Commerce Committee
September 19, 2014
Kevin [email protected]